Strata Critical Medical will release its financial results for the second quarter ended July 31, 2026 on Tuesday, August 4, 2026 before the market opens. The company will host a conference call on the same day at 8:00 am Eastern Time to discuss the performance. The call will feature a question-and-answer session for participants.

The conference call will be hosted by Melissa Tomkiel, Co-Chief Executive Officer and General Counsel, and Will Heyburn, Co-Chief Executive Officer and Chief Financial Officer. Investors can join the live call by registering online to receive a dial-in number and unique PIN.

An audio-only webcast of the call will be accessible via the Investors section of the Strata Critical Medical website. A replay of the webcast will be available for one year following the event.

Strata Critical Medical provides time-critical logistics and medical services to the U.S. healthcare industry. The company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations. Its core services include air and ground logistics, surgical organ recovery, and organ placement.

The company also offers normothermic regional perfusion for the transplant industry, along with perfusion staffing and equipment solutions for cardiovascular surgery centers. These services are offered under the Trinity Medical Solutions and Keystone Perfusion brands.

Strata Critical Medical, Inc. has completed the acquisition of Heart and Lung Transplant National Recovery Program (HLT-NRP), a provider of transplant surgical recovery services in the United States, for a total transaction value of $21.5 million. This acquisition expands Strata's capabilities in the transplant sector by integrating HLT-NRP's specialized recovery services and network of experienced transplant surgeons in key markets such as Florida and California.

The deal structure comprises approximately 80% cash and 20% stock. The stock component will be released from a multi-year lockup, contingent upon the seller's continued participation in the business operations following the acquisition. The transaction was completed at a mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata’s capital deployment strategy.

Strategic Impact and Financial Outlook

The acquisition adds significant scale to Transplant Clinical, Strata’s fastest growing business line. For the full year 2026, HLT-NRP is expected to generate revenue of approximately $10.0 million and Adjusted EBITDA of approximately $3.1 million. Management indicated that the combined growth and operational synergies are expected to quickly lower the effective purchase price and maximize returns.

Transaction Details

The acquisition marks a strategic expansion for Strata Critical Medical, strengthening its service offerings in the transplant surgical recovery market and enhancing responsiveness to the transplant community.